EXAS | Exact Sciences Corporation

Market Cap (In USD)

10.61 Billion

Revenue (In USD)

2.49 Billion

Net Income (In USD)

-204.14 Million

Avg. Volume

2.68 Million

Company Profile

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Mr. Kevin T. Conroy
Employee Count: -
Website: https://www.exactsciences.com
Ipo Date: 2001-02-01
Details: Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.